This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meunier, P. J. Articles by Balena, R. Search for Related Content PubMed PubMed Citation Articles by Meunier, P. J. Articles by Balena, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 1-HYDROXY-1,1-DIPHOSPHONOETHANE Medline Plus Health Information Osteoporosis

Prevention of Early Postmenopausal Bone Loss with Cyclical Etidronate Therapy (A Double-Blind, Placebo-Controlled Study and 1-Year Follow-Up)¹

Department of Rheumatology & Bone Disease (P.J.M., E.C., I.T., C.H., P.D.D.) Pavillon F, Edouard Herriot Hospital, 69437 Lyon, France; and Procter and Gamble Pharmaceuticals (R.B.), European Research and Development, Staines, Middx, TW 18 3AZ United Kingdom

Address all correspondence and requests for reprints to: Professeur P. J. Meunier, M.D, Hôpital Edouard Herriot, Pavillon F (Rhumatologie & Pathologie Osseuse), 69437 Lyon cedex 3, France.

The objective of the study was to evaluate the effects of cyclical therapy with etidronate and calcium on spinal and femoral bone loss in the early post menopausal period. Fifty-four women, 53 ± 2.8 yr old (mean ± SD) and 2.3 ± 1.3 yr post menopause received oral doses of either 400 mg/day etidronate for 2 weeks followed by 500 mg/day elemental calcium for 11 weeks, or placebo for 14 days followed by calcium for 11 weeks, repeated over a total of 24 months. A statistically significant increase in spinal bone mineral density (BMD) was observed after 6 months in the etidronate group. At 2 yr, the mean treatment differences in spinal and femoral neck BMD were +2.93% (P < 0.02) and 2.02% (P < 0.03), respectively. Serum osteocalcin and urinary crossLaps/creatinine excretion were decreased signficantly by etidronate. Etidronate was well tolerated with a safety profile similar to that of placebo.

Thirty-seven women participated in a 1-yr open-label follow-up study. Twelve months after treatment withdrawal, spinal BMD in the former etidronate group decreased by 1.43% and serum osteocalcin and urinary crossLaps returned to pretreatment values.

In conclusion, cyclical etidronate is an effective therapy for the prevention of both trabecular and cortical bone loss in the early menopause and has a good safety profile.

This article has been cited by other articles:

				A. Qaseem, V. Snow, P. Shekelle, R. Hopkins Jr., M. A. Forciea, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, September 16, 2008; 149(6): 404 - 415. [Abstract] [Full Text] [PDF]

				C. MacLean, S. Newberry, M. Maglione, M. McMahon, V. Ranganath, M. Suttorp, W. Mojica, M. Timmer, A. Alexander, M. McNamara, et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis Ann Intern Med, February 5, 2008; 148(3): 197 - 213. [Abstract] [Full Text] [PDF]

				J. P. Brown and R. G. Josse Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada Can. Med. Assoc. J., March 18, 2003; 168(90060): SF1 - 38. [Abstract] [Full Text] [PDF]

				J. P. Brown and R. G. Josse 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada Can. Med. Assoc. J., November 12, 2002; 167(90100): s1 - 34. [Abstract] [Full Text] [PDF]

				P. Ravn, S. R. Weiss, J. A. Rodriguez-Portales, M. R. McClung, R. D. Wasnich, N. L. Gilchrist, P. Sambrook, I. Fogelman, D. Krupa, A. J. Yates, et al. Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1492 - 1497. [Abstract] [Full Text]

				P. Ravn, D. Hosking, D. Thompson, G. Cizza, R. D. Wasnich, M. McClung, A. J. Yates, N. H. Bjarnason, and C. Christiansen Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2363 - 2368. [Abstract] [Full Text]

				S. COWAN, S. MORIN, and P. ERNST Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases Thorax, May 1, 1998; 53(5): 331 - 332. [Full Text]

				C. Rosen Evolving Toward a New Paradigm for Prevention of Osteoporosis-- The Time Is Upon Us J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2782 - 2783. [Full Text] [PDF]